TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Incyte Biosciences Nordic AB
Closing information (x1000 EUR)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
3,482
|
2,943
|
2,818 |
Financial expenses |
1
|
4
|
3 |
Earnings before taxes |
157
|
126
|
149 |
EBITDA |
154
|
139
|
169 |
Total assets |
1,166
|
1,508
|
1,560 |
Current assets |
977
|
1,497
|
1,539 |
Current liabilities |
704
|
1,143
|
1,244 |
Equity capital |
462
|
365
|
316 |
- share capital |
5
|
4
|
5 |
Employees (average) |
10
|
9
|
7 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
39.6%
|
24.2%
|
20.3% |
Turnover per employee |
348
|
327
|
403 |
Profit as a percentage of turnover |
4.5%
|
4.3%
|
5.3% |
Return on assets (ROA) |
13.6%
|
8.6%
|
9.7% |
Current ratio |
138.8%
|
131.0%
|
123.7% |
Return on equity (ROE) |
34.0%
|
34.5%
|
47.2% |
Change turnover |
531
|
354
|
722 |
Change turnover % |
18%
|
14%
|
34% |
Chg. No. of employees |
1
|
2
|
1 |
Chg. No. of employees % |
11%
|
29%
|
17% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.